In ₹ Crore except Per Share Latest Annual | ZYDUSLIFE FY26 | SUNPHARMA FY26 | DRREDDY FY26 | CIPLA FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 22.33× | 38.70× | 22.63× | 28.61× | 28.61× -22% | |
| P/B | 3.80× | 5.29× | ◆ 2.49× | 3.22× | 3.22× +18% | |
| EV/EBITDA | ◆ 13.88× | 23.53× | 14.91× | 17.43× | 17.43× -20% | |
| Market Cap | ₹1.13L Cr | ₹4.44L Cr | ₹95,274 Cr | ₹1.11L Cr | ₹1.11L Cr +1% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 16.35% | 10.03% | 10.96% | 7.37% | 10.03% +63% | |
| Revenue CAGR 5Y | ◆ 12.45% | 11.78% | 12.09% | 8.01% | 11.78% +6% | |
| Net Income CAGR 3Y | ◆ 34.80% | 10.57% | -2.66% | 10.88% | 10.57% +229% | |
| Revenue YoY (latest Q) | ◆ 21.96% | 10.46% | -5.51% | 2.33% | 2.33% +842% | |
| Net Income YoY (latest Q) | -34.90% | ◆ 26.53% | -69.10% | -39.18% | -39.18% +11% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 31.22% | 30.33% | 19.15% | 20.89% | 20.89% +49% | |
| Net Income Margin | 18.87% | ◆ 19.69% | 12.34% | 13.71% | 13.71% +38% | |
| Return on Common Equity | ◆ 17.04% | 13.69% | 10.98% | 11.24% | 11.24% +52% | |
| Return on Capital Employed | ◆ 19.26% | 17.17% | 10.62% | 13.17% | 13.17% +46% | |
| Return on Assets | 9.78% | ◆ 10.58% | 7.15% | 9.09% | 9.09% +8% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.40× | 0.05× | 0.16× | ◆ 0.01× | 0.05× +700% | |
| Interest Coverage | 16.10× | 43.65× | 11.76× | ◆ 85.90× | 43.65× -63% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹27,148 Cr | ₹58,462 Cr | ₹33,700 Cr | ₹28,163 Cr | ₹33,700 Cr -19% | |
| Net Income | ₹5,124 Cr | ₹11,509 Cr | ₹4,158 Cr | ₹3,862 Cr | ₹4,158 Cr +23% | |
| Total Assets | ₹52,407 Cr | ₹1.09L Cr | ₹58,123 Cr | ₹42,496 Cr | ₹58,123 Cr -10% | |
| EPS | ₹50.09 | ₹47.8 | ₹50.41 | ₹48.03 | ₹48.03 +4% | |
| Book Value per Share | ₹294.06 | ₹349.6 | ₹457.86 | ₹427.34 | ₹427.34 -31% | |